Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-22. (Cancelled).

23. (New) A humanized antibody binding to CD47, comprising:

(1) a heavy chain variable region containing the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 99; and the sequence of aa 1-30 (FR1) and the sequence of aa 36-49 (FR2) of SEQ ID NO: 99; and

(2) a light chain variable region containing the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 106; and the sequence of aa 40-54 (FR2) of SEQ ID NO: 106.

24. (New) A humanized antibody binding to CD47, comprising:

(1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO: 99; and

(2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO: 106.

25. (New) The humanized antibody of claim 23, wherein the sequence of aa 40-54 (FR2) of SEQ ID NO: 106 is replaced with the sequence of aa 159-175 (FR2) of SEQ ID NO: 92.

26. (New) The humanized antibody of any one of claims 23, which is a small antibody fragment containing an antigen-binding domain.

27. (New) The humanized antibody of any one of claims 24, which is a small antibody fragment containing an antigen-binding domain.

28. (New) The humanized antibody of claim 26, which is a diabody.

29. (New) The humanized antibody of claim 27, which is a diabody.

30. (New) The humanized antibody of claim 28, which is a single-chain diabody.

31. (New) The humanized antibody of claim 29, which is a single-chain diabody.

32. (New) The humanized antibody of claim 26, wherein a disulfide bond exists between diabody-forming fragments.

33. (New) The humanized antibody of claim 27, wherein a disulfide bond exists between diabody-forming fragments.

34. (New) The humanized antibody of claim 32, further comprising:

(1) an antibody having the amino acid sequence of SEQ ID NO: 90; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

35. (New) The humanized antibody of claim 33, further comprising:

(1) an antibody having the amino acid sequence of SEQ ID NO: 90; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

36. (New) The humanized antibody of claim 32, further comprising:

(1) an antibody having the amino acid sequence of SEQ ID NO: 92; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

37. (New) The humanized antibody of claim 33, further comprising:

(1) an antibody having the amino acid sequence of SEQ ID NO: 92; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

38. (New) An antibody binding to CD47, comprising any one of:

(1) the sequence of aa 1-234 of SEQ ID NO: 110; and

(2) the sequence of aa 1-483 of SEQ ID NO: 113.

39. (New) A therapeutic agent for a hematological disorder, comprising a therapeutically effective amount of the antibody of claim 23 and a pharmaceutically acceptable carrier.

40. (New) A therapeutic agent for a hematological disorder, comprising a therapeutically effective amount of the antibody of claim 24 and a pharmaceutically acceptable carrier.

41. (New) A therapeutic agent for a hematological disorder, comprising a therapeutically effective amount of the antibody of claim 38 and a pharmaceutically acceptable carrier.

42. (New) The therapeutic agent of claim 39, wherein the hematological disorder is selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma, aplastic anemia, myelodysplastic syndromes, and polycythemia vera.

43. (New) The therapeutic agent of claim 40, wherein the hematological disorder is selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma, aplastic anemia, myelodysplastic syndromes, and polycythemia vera.

acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma, aplastic anemia, myelodysplastic syndromes, and polycythemia vera.